137310.KO SD Biosensor Inc
- Market cap
- KRW 799B
- P/E
- -
- P/B
- 0.32x
- ROE
- 3.3%
- Dividend yield
- 3.03%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 137310.KO undervalued?
Graham numberThe Graham number of SD Biosensor Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SD Biosensor Inc fundamental analysis
No fundamental analysis for SD Biosensor Inc yet.
SD Biosensor Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SD Biosensor Inc
SD Biosensor, Inc., together with its subsidiaries, operates as an in-vitro diagnostic company in South Korea, India, Asia, Europe, the Americas, and Africa. The company offers STANDARD Q, which provides rapid diagnostic products; STANDARD F, a fluorescence immunodiagnostic system for various qualitative and quantitative diagnosis items; STANDARD E, an enzyme immunoassay diagnosis for large-volume tests; and STANDARD M, a field molecular diagnosis system for infectious disea…
Full company profileSD Biosensor Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SD Biosensor Inc annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 73.0B | 1.69T | 2.93T | 2.93T | 656B | 695B | 711B | 760B |
| Gross Profit | 20.8B | 858B | 1.57T | 1.39T | 126B | 339B | 326B | 387B |
| Operating Income | 1.52B | 738B | 1.36T | 1.15T | -248B | -54.1B | -80.9B | -37.7B |
| EBITDA | 6.78B | 726B | 1.46T | 1.28T | -252B | -8.90B | -676B | 221B |
| Net Income | 3.15B | 616B | 1.06T | 911B | -468B | -98.4B | -512B | 78.3B |
| EPS | 34 | 6,597 | 10,362 | 8,913 | -3,823 | -804 | -4,281 | 655 |
| Balance Sheet | ||||||||
| Total Assets | 170B | 1.46T | 3.01T | 3.26T | 3.79T | 3.89T | 3.24T | 2.90T |
| Total Liabilities | 31.8B | 704B | 802B | 315B | 957B | 956B | 906B | 496B |
| Shareholders' Equity | 133B | 748B | 2.19T | 2.94T | 2.82T | 2.92T | 2.33T | 2.40T |
| Cash & Short-term Investments | 19.2B | 243B | 882B | 1.87T | 482B | 177B | 367B | 230B |
| Cash Flow | ||||||||
| Operating Cash Flow | -1.62B | 495B | 1.23T | 890B | -242B | 157B | 358B | -5.18B |
| Capital Expenditure | 7.45B | 54.9B | 190B | 300B | 145B | 80.9B | 57.5B | 41.7B |
| Free Cash Flow | -9.13B | 440B | 1.14T | 590B | -387B | 75.6B | 300B | -46.8B |
| Ratios | ||||||||
| ROE | 2.4% | 82.3% | 48.6% | 31.0% | -16.6% | -3.4% | -22.0% | 3.3% |
| ROA | 1.9% | 42.1% | 35.4% | 27.9% | -12.3% | -2.5% | -15.8% | 2.7% |
| Net Profit Margin | 4.3% | 36.5% | 36.3% | 31.1% | -71.3% | -14.2% | -72.1% | 10.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SD Biosensor Inc dividends
- Dividend yield
- 3.03%
- Forward dividend
- 200.00 KRW
- Payout ratio
- -
- Ex-dividend date
- Mar 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 24.2B | 202 | - |
| 2024 | KRW 38.1M | 0.31 | - |
| 2023 | KRW 29.5B | 242 | - |
| 2022 | KRW 199B | 1,944 | 21.8% |
| 2021 | KRW 49.8B | 485 | 4.7% |
| 2020 | KRW 49.8B | 534 | 8.1% |
| 2019 | KRW 49.8B | 534 | 1,580.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns SD Biosensor Inc
- Insiders 72.77%
- Institutions 2.40%
- Public & others 24.82%
- Shares outstanding 120M
- Free float 32.0M
SD Biosensor Inc company profile
- Company name
- SD Biosensor Inc
- Ticker
- 137310.KO
- ISIN
- KR7137310009
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 616
- Fiscal year end
- December
- Address
- C-4&5Floor, Suwon-si, South Korea, 16690
- Phone
- 82 31 300 0400
- Website
- sdbiosensor.com
About SD Biosensor Inc
SD Biosensor, Inc., together with its subsidiaries, operates as an in-vitro diagnostic company in South Korea, India, Asia, Europe, the Americas, and Africa. The company offers STANDARD Q, which provides rapid diagnostic products; STANDARD F, a fluorescence immunodiagnostic system for various qualitative and quantitative diagnosis items; STANDARD E, an enzyme immunoassay diagnosis for large-volume tests; and STANDARD M, a field molecular diagnosis system for infectious disease diagnosis, drug resistance, and genetic testing. It also provides STANDARD i, an analyzer based on chemiluminescence immunoassay technology for detection of clinical biomarkers, including hormones, tumor markers, and infectious diseases; blood glucose meter products; and other products, such as transport medium, d-BLOCK incubator, G6PD analyzer, LipidoCare analyzer, MultiCare analyzer, and Pilot COVID-19 at-home test. The company exports its products. SD Biosensor, Inc. was founded in 1999 and is headquartered in Suwon-si, South Korea.
SD Biosensor Inc management
3- Hyo Keun LeeVice Chairman & CEO
- Tae Young HeoPresident & CEO
- Chul-Gyu OhCFO & Director